EAM Investors’s Anavex Life Sciences AVXL Stock Holding History

EAM Investors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-177,728	Closed	-$4.06M	–	291
2021 Q2	$4.06M	Buy	+177,728	New	+$2.63M	0.63%	20

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

EAM Investors's AVXL Position: Q3 2021 in Review

EAM Investors sold out of Anavex Life Sciences (AVXL) in Q3 2021, closing a stake of 177,728 shares — an estimated $4.06M sold.

EAM Investors first reported a position in AVXL in Q2 2021 and held it in 1 quarter. The position peaked at $4.06M in Q2 2021. 136 funds tracked by Wall St. Rank hold AVXL as of Q3 2021.

EAM Investors reported no remaining Anavex Life Sciences position as of Q3 2021 after selling out during the quarter.
EAM Investors sold 177,728 Anavex Life Sciences shares in Q3 2021, an estimated $4.06M.
EAM Investors first reported a position in Anavex Life Sciences in Q2 2021 and held it in 1 quarter.
EAM Investors's Anavex Life Sciences position peaked at $4.06M in Q2 2021.
136 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2021.

Based on EAM Investors's 13F filing for Q3 2021, filed 12 Nov 2021.